BR112019016300A2 - ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO - Google Patents
ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO Download PDFInfo
- Publication number
- BR112019016300A2 BR112019016300A2 BR112019016300-0A BR112019016300A BR112019016300A2 BR 112019016300 A2 BR112019016300 A2 BR 112019016300A2 BR 112019016300 A BR112019016300 A BR 112019016300A BR 112019016300 A2 BR112019016300 A2 BR 112019016300A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- same
- fxi
- preparation
- pharmaceutical composition
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100030563 Coagulation factor XI Human genes 0.000 abstract 1
- 108010074864 Factor XI Proteins 0.000 abstract 1
- 108010080805 Factor XIa Proteins 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710073984.XA CN108409863B (zh) | 2017-02-10 | 2017-02-10 | 抗凝血因子xi抗体 |
| CN201710073984.X | 2017-02-10 | ||
| PCT/CN2017/119856 WO2018145533A1 (zh) | 2017-02-10 | 2017-12-29 | 抗凝血因子xi抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019016300A2 true BR112019016300A2 (pt) | 2020-06-16 |
Family
ID=63107934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019016300-0A BR112019016300A2 (pt) | 2017-02-10 | 2017-12-29 | ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3581587B1 (enExample) |
| JP (1) | JP7271430B2 (enExample) |
| KR (1) | KR102690437B1 (enExample) |
| CN (1) | CN108409863B (enExample) |
| AU (2) | AU2017397778B2 (enExample) |
| BR (1) | BR112019016300A2 (enExample) |
| CA (1) | CA3054322A1 (enExample) |
| MX (1) | MX2019009500A (enExample) |
| WO (1) | WO2018145533A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020029179A1 (en) * | 2018-08-09 | 2020-02-13 | Shanghai Benemae Pharmaceutical Corporation | Anti-factor xi antibodies |
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| CN110878123B (zh) * | 2018-09-05 | 2022-08-23 | 华瑞同康生物技术（深圳）有限公司 | 一种抗tk1原核重组单链抗体及制备方法 |
| EP3914624A4 (en) * | 2019-01-21 | 2022-10-19 | Aronora, Inc. | NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECTS AND ASSOCIATED USES |
| CN113474374B (zh) * | 2019-04-16 | 2025-05-02 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
| CN110423278B (zh) | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| CN110498839A (zh) * | 2019-09-19 | 2019-11-26 | 河南省农业科学院 | 氟罗沙星单链抗体关键多肽序列及应用 |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| TWI882142B (zh) * | 2020-07-02 | 2025-05-01 | 大陸商北京拓界生物醫藥科技有限公司 | 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途 |
| CN116589588B (zh) * | 2023-04-14 | 2023-12-22 | 北京基科晟斯医药科技有限公司 | 结合凝血因子x的抗体 |
| WO2025130748A1 (zh) * | 2023-12-22 | 2025-06-26 | 四川科伦博泰生物医药股份有限公司 | 一种抗凝血因子XI/XIa抗体制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2981754B2 (ja) * | 1990-02-02 | 1999-11-22 | 第一化学薬品株式会社 | 血液凝固第▲ｘ▼▲ｉｉｉ▼因子に対するモノクロナール抗体 |
| KR100925348B1 (ko) * | 2001-06-12 | 2009-11-09 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 인간형 항-혈액 응고 인자 ⅷ 항체 |
| DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
| AU2008326348B2 (en) | 2007-11-21 | 2014-01-30 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
| AU2009335643B2 (en) * | 2008-12-18 | 2014-05-29 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| SI2847228T1 (sl) * | 2012-05-10 | 2018-11-30 | Bayer Pharma Aktiengesellschaft | Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe |
| JOP20200312A1 (ar) * | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| EP3325010B1 (en) * | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Antibodies to coagulation factor xia and uses thereof |
-
2017
- 2017-02-10 CN CN201710073984.XA patent/CN108409863B/zh active Active
- 2017-12-29 CA CA3054322A patent/CA3054322A1/en active Pending
- 2017-12-29 MX MX2019009500A patent/MX2019009500A/es unknown
- 2017-12-29 AU AU2017397778A patent/AU2017397778B2/en active Active
- 2017-12-29 BR BR112019016300-0A patent/BR112019016300A2/pt unknown
- 2017-12-29 JP JP2019543277A patent/JP7271430B2/ja active Active
- 2017-12-29 EP EP17895532.4A patent/EP3581587B1/en active Active
- 2017-12-29 WO PCT/CN2017/119856 patent/WO2018145533A1/zh not_active Ceased
- 2017-12-29 KR KR1020197025752A patent/KR102690437B1/ko active Active
-
2025
- 2025-05-08 AU AU2025203303A patent/AU2025203303A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190116990A (ko) | 2019-10-15 |
| MX2019009500A (es) | 2020-01-30 |
| JP7271430B2 (ja) | 2023-05-11 |
| EP3581587A1 (en) | 2019-12-18 |
| KR102690437B1 (ko) | 2024-07-30 |
| AU2025203303A1 (en) | 2025-05-29 |
| EP3581587A4 (en) | 2021-03-31 |
| CN108409863A (zh) | 2018-08-17 |
| AU2017397778A1 (en) | 2019-10-03 |
| WO2018145533A1 (zh) | 2018-08-16 |
| RU2019128423A3 (enExample) | 2021-03-19 |
| EP3581587B1 (en) | 2025-02-05 |
| CA3054322A1 (en) | 2018-08-16 |
| CN108409863B (zh) | 2023-09-26 |
| JP2020507578A (ja) | 2020-03-12 |
| AU2017397778B2 (en) | 2025-03-06 |
| RU2019128423A (ru) | 2021-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019016300A2 (pt) | ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| BR112018009064A8 (pt) | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo | |
| BR112019008458A2 (pt) | 1,2,4-triazolonas 2,4,5-trisubstituídas. | |
| CL2018002826A1 (es) | Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
| BR112019006463A2 (pt) | composição oral de canabinoides extraídos e métodos de uso da mesma | |
| BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
| CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
| BR112019006853A2 (pt) | composição farmacêutica líquida | |
| BR112019004691A2 (pt) | inibidores bicíclicos em espiro da interação menina-mll | |
| CL2021001613A1 (es) | Derivados de oxopiridina sustituidos | |
| BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
| BR112013001296A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112021021230A8 (pt) | Forma de cristal de composto inibidor de wee1 e uso do mesmo | |
| BR112021018918A2 (pt) | Compostos e composições como moduladores de sinalização de tlr | |
| EP3685840A4 (en) | PHARMACEUTICAL COMPOSITION OF COMPOUNDS FOR TREATING INFLAMMATORY SKIN DISEASES | |
| PT3604304T (pt) | Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase | |
| MX2019013137A (es) | Metodos y composiciones para tratar enfermedades oculares alergicas. | |
| BR112018015090A2 (pt) | anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| BR112013025906A2 (pt) | "preparação farmacêutica compreendendo anticorpos imunoglobulina y ou seus fragmentos, e seu uso". |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |